mometasone furoate 0.025 MG/ACTUAT / olopatadine hydrochloride 0.665 MG/ACTUAT Metered Dose Nasal Spray [Ryaltris]
mometasone furoate
RxCUI: 2591812
What the CMS Formulary Data Shows for mometasone furoate 0.025 MG/ACTUAT / olopatadine hydrochloride 0.665 MG/ACTUAT Metered Dose Nasal Spray [Ryaltris]
Per the CMS 2026 Part D formulary file, mometasone furoate 0.025 MG/ACTUAT / olopatadine hydrochloride 0.665 MG/ACTUAT Metered Dose Nasal Spray [Ryaltris] (RxNorm concept RXCUI 2591812, generic name mometasone furoate) appears on 14 distinct formulary files spanning 1,025 Medicare Part D plan offerings - 20.2% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 3 to Tier 4, with a cross-plan average of Tier 3.7.
Real-world access to mometasone furoate 0.025 MG/ACTUAT / olopatadine hydrochloride 0.665 MG/ACTUAT Metered Dose Nasal Spray [Ryaltris] depends on utilization management as much as tier placement: 7.1% of covering formularies require prior authorization. 42.9% require step therapy. 7.1% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 490,025 Part D beneficiaries filled mometasone furoate 0.025 MG/ACTUAT / olopatadine hydrochloride 0.665 MG/ACTUAT Metered Dose Nasal Spray [Ryaltris] in 2023, with total plan-and-beneficiary spending of $54,728,321 and an average per-beneficiary annual cost of $111.68. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry mometasone furoate 0.025 MG/ACTUAT / olopatadine hydrochloride 0.665 MG/ACTUAT Metered Dose Nasal Spray [Ryaltris] today.
Coverage Details
- Formularies covering
- 14
- Plans covering
- 1,025
- Coverage rate
- 20.2%
- Tier range
- Tier 3 – Tier 4
- Average tier
- Tier 4, Non-Preferred
Restrictions
- Prior authorization required
- 7.1% of formularies
- Step therapy required
- 42.9% of formularies
- Quantity limits
- 7.1% of formularies
2023 Medicare Spending
- Beneficiaries
- 490,025
- Total spending
- $54,728,321
- Avg per beneficiary
- $111.68
Tier Distribution Across Plans
Standalone Drug Plans (PDP) Covering mometasone furoate 0.025 MG/ACTUAT / olopatadine hydrochloride 0.665 MG/ACTUAT Metered Dose Nasal Spray [Ryaltris]
2 standalone prescription drug plans include this drug.
| Plan | Insurer | Tier | PA | ST | Premium | States |
|---|---|---|---|---|---|---|
| AARP Medicare Rx Preferred from UHC (PDP) | UNITEDHEALTHCARE INS. CO. & UHC INS. CO. OF NY | T3 | No | No | $0 | - |
| AARP Medicare Rx Preferred from UHC (PDP) | UNITEDHEALTHCARE INS. CO. & UHC INS. CO. OF NY | T3 | No | No | $0 | - |
Medicare Advantage Plans (MA-PD) Covering mometasone furoate 0.025 MG/ACTUAT / olopatadine hydrochloride 0.665 MG/ACTUAT Metered Dose Nasal Spray [Ryaltris]
98 Medicare Advantage plans with Part D drug coverage include this drug.
Frequently Asked Questions
Is mometasone furoate 0.025 MG/ACTUAT / olopatadine hydrochloride 0.665 MG/ACTUAT Metered Dose Nasal Spray [Ryaltris] covered by Medicare Part D?
Yes, mometasone furoate 0.025 MG/ACTUAT / olopatadine hydrochloride 0.665 MG/ACTUAT Metered Dose Nasal Spray [Ryaltris] is covered by 1,025 Medicare Part D plans (20.2% of all Part D formularies).
What tier is mometasone furoate 0.025 MG/ACTUAT / olopatadine hydrochloride 0.665 MG/ACTUAT Metered Dose Nasal Spray [Ryaltris] on Medicare Part D plans?
mometasone furoate 0.025 MG/ACTUAT / olopatadine hydrochloride 0.665 MG/ACTUAT Metered Dose Nasal Spray [Ryaltris] averages Tier 3.7 across Part D plans, ranging from Tier 3 to Tier 4.
Does mometasone furoate 0.025 MG/ACTUAT / olopatadine hydrochloride 0.665 MG/ACTUAT Metered Dose Nasal Spray [Ryaltris] require prior authorization?
7.1% of Part D formularies require prior authorization for mometasone furoate 0.025 MG/ACTUAT / olopatadine hydrochloride 0.665 MG/ACTUAT Metered Dose Nasal Spray [Ryaltris]. Step therapy: 42.9%. Quantity limits: 7.1%.
How much does Medicare spend on mometasone furoate 0.025 MG/ACTUAT / olopatadine hydrochloride 0.665 MG/ACTUAT Metered Dose Nasal Spray [Ryaltris]?
In 2023, total Medicare Part D spending on mometasone furoate 0.025 MG/ACTUAT / olopatadine hydrochloride 0.665 MG/ACTUAT Metered Dose Nasal Spray [Ryaltris] was $54,728,321, covering 490,025 beneficiaries. The average spend per beneficiary was $111.68.
Read our methodology - how this data is sourced, computed, and verified.